Gamma Globulin Observations and Outcomes Database for Specific Home Infusion Evidence, Patient Care And Research Data (GOOD-SHEPARD)

B

BriovaRx Infusion Services

Status

Terminated

Conditions

Intravenous Immunoglobulin (IVIg) Therapy in a Home Infusion Setting

Study type

Observational

Funder types

Industry

Identifiers

NCT01774331
AHS1-12-001

Details and patient eligibility

About

Primary: • Demonstrate the utility of a new electronic data capture (EDC) system (CareExchange™) using infusion nurse measured physical, quality of life (QOL), respiratory, and disability assessments. Secondary: Change in Intravenous Immunoglobulin (IVIg) dose effects measured outcomes. Change in IVIg dose and timing effects measured outcomes. Change in patient status is reflected in measured outcomes. Assess the value to physicians from infusion nurse collected outcomes data. Identify types of patients by response to IVIg therapy (i.e. natural or poor responders). Change in response rate to IVIg therapy by disease state and demographics.

Full description

This is a prospective, observational evaluation of immunoglobulin (Ig) therapy in consenting adult and assenting pediatric subjects who receive infusion services from BriovaRx Infusion Services, (Formerly AxelaCare Health Solutions, LLC). Subjects meeting all inclusion criteria who have provided informed consent/assent for trial participation will have validated, physician-prescribed, and standard-of-care outcome measures recorded during normal home infusion visits. Collected data will be de-identified and aggregated into cohorts of like diagnosis for trend analysis.

Enrollment

11 patients

Sex

All

Ages

7+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age at enrollment ≥ 7
  • Sign informed consent/assented to participation
  • Ability to read and write English
  • Understanding of study procedures and ability to comply with study procedures for the entire length of the study
  • Receiving IVIg under the discretion of the patient's treating physician in accordance with standard treatment practices
  • Have been on or is between doses of IVIg under the discretion of the patient's treating physician in accordance with standard treatment practices
  • Being considered to be prescribed IVIg under the discretion of the patient's treating physician in accordance with standard treatment practices
  • Determined to be clinically eligible for infusion services by BriovaRx Infusion Services (Formerly AxelaCare Health Solutions, LLC.) in collaboration with the patient's prescribing physician

Exclusion criteria

  • Children (age ≤ 6 years)
  • Prisoners, and other wards of the state

Trial design

11 participants in 1 patient group

Immunoglobulin Therapy
Description:
Immunoglobulin Therapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems